Bausch Health Companies (BHC) Non-Current Debt (2009 - 2026)
Bausch Health Companies' (BHC) quarterly Non-Current Debt came in at $19.9 billion in Q1 2026, down 6.37% year-on-year from $21.2 billion in Q1 2025, and down 3.48% quarter-over-quarter from $20.6 billion in Q4 2025.
Bausch Health Companies (BHC) Non-Current Debt (2009 - 2026) Analysis & Trends
Bausch Health Companies has disclosed Non-Current Debt across 18 years of filings, most recently posting $19.9 billion for Q1 2026.
- Non-Current Debt for Q1 2026 came in at $19.9 billion, down 6.37% year-over-year; the trailing twelve-month figure through Mar 2026 was $19.9 billion (down 6.37% YoY), and the FY2025 annual result was $20.6 billion, up 8.71% from the prior year.
- Non-Current Debt came in at $19.9 billion for Q1 2026 at Bausch Health Companies, down from $20.6 billion in the prior quarter.
- In the past five years, Non-Current Debt ranged from a high of $23.2 billion in Q1 2022 to a low of $18.9 billion in Q4 2024.
- The 5-year median for Non-Current Debt is $20.9 billion (2025), against an average of $20.9 billion.
- Across the five-year window, Non-Current Debt decreased 13.66% in 2024 and grew 8.71% in 2025, its largest moves.
- Bausch Health Companies' Non-Current Debt stood at $20.3 billion in 2022, then gained by 7.89% to $21.9 billion in 2023, then fell by 13.66% to $18.9 billion in 2024, then gained by 8.71% to $20.6 billion in 2025, then fell by 3.48% to $19.9 billion in 2026.
- The last three Non-Current Debt figures came in at $19.9 billion (Q1 2026), $20.6 billion (Q4 2025), and $20.5 billion (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 38.34 Bn | 34.60 Bn | 1.97 Bn | 14.02 Bn |
| 2 | Zoetis | 33.27 Bn | 31.33 Bn | 1.62 Bn | 9.05 Bn |
| 3 | United Therapeutics | 23.75 Bn | 21.60 Bn | 648.10 Mn | - |
| 4 | Aurora Cannabis | 17.11 Bn | 17.03 Bn | 33.43 Mn | - |
| 5 | Neurocrine Biosciences | 16.37 Bn | 15.05 Bn | 800.70 Mn | - |
| 6 | Elanco Animal Health | 11.78 Bn | 11.35 Bn | 785.00 Mn | 3.92 Bn |
| 7 | Alkermes | 7.05 Bn | 6.54 Bn | -116.06 Mn | 1.48 Bn |
| 8 | Lantheus Holdings | 6.49 Bn | 5.99 Bn | 230.92 Mn | 569.60 Mn |
| 9 | Hims & Hers Health | 6.19 Bn | 5.44 Bn | 396.79 Mn | - |
| 10 | Bausch Health Companies | 1.91 Bn | 1.58 Bn | 2.48 Bn | 19.88 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 19.88 Bn |
| Mar 31, 2026 | 19.88 Bn |
| Dec 31, 2025 | 20.59 Bn |
| Dec 31, 2025 | 20.59 Bn |
| Sep 30, 2025 | 20.46 Bn |
| Sep 30, 2025 | 20.46 Bn |
| Jun 30, 2025 | 20.86 Bn |
| Jun 30, 2025 | 20.86 Bn |
| Mar 31, 2025 | 21.23 Bn |
| Mar 31, 2025 | 21.23 Bn |
| Dec 31, 2024 | 18.94 Bn |
| Dec 31, 2024 | 18.94 Bn |
| Sep 30, 2024 | 21.05 Bn |
| Sep 30, 2024 | 21.05 Bn |
| Jun 30, 2024 | 21.21 Bn |
| Jun 30, 2024 | 21.21 Bn |
| Mar 31, 2024 | 21.54 Bn |
| Mar 31, 2024 | 21.54 Bn |
| Dec 31, 2023 | 21.94 Bn |
| Dec 31, 2023 | 21.94 Bn |